Contrave Combines Naltrexone and Bupropion. The LIGHT Trial Cardiovascular Safety Data Is What Men with Obesity Need to Know.

The Opening Scene

The following is a composite of patients I have seen in clinic. Names and identifying details are changed.

Marcus is 51 years old. He runs a logistics company out of Indianapolis and drives 40,000 miles a year visiting distribution centers. He is not the kind of man who asks for help with his weight. He is the kind of man who has tried things on his own: two stretches of intermittent fasting, a Peloton that now holds his gym bag, and one period in 2021 when he lost 22 pounds before a work project swallowed the next four months. He came back to me not because of his weight. He came back because his coronary calcium score was 347.

CAC 347. Age 51. No prior heart attack, no symptoms. But a calcium score that put him in the 85th percentile for his age and sex. His LDL was 108 but his ApoB was 131. His hs-CRP was 3.4. His fasting insulin was 22. He was not diabetic. He was pre-metabolic: the storm before the event.

We talked about statins. He was already on rosuvastatin 20 mg. We talked about ezetimibe. We talked about what else we could move. And then I asked the question I ask every man in that cardiac-metabolic corridor: “Tell me about how you eat. Not what you think you should eat. How you actually eat.”

What Marcus described took about four minutes. Late-night eating that he could not fully explain. A pull toward food in the 9 PM to 11 PM window that was not hunger, not really, but something more like a repetitive thought that could only be satisfied by acting on it. He called it “noise.” He said: “I know I should stop. I keep not stopping.”

That word, noise, is the clinical tell for the Contrave conversation. Not every person who needs to lose weight is a Contrave candidate. The person with food noise, whose eating has a compulsive texture that sits somewhere between craving and habit, who knows the right answer and cannot execute it: that is the phenotype that deserves a specific pharmacological consideration. Contrave works on the circuitry of reward, not the circuitry of satiety. That distinction matters when you are writing a prescription.

I put Marcus on rosuvastatin 40 mg, ezetimibe 10 mg, and started the Contrave conversation. The cardiac question was not whether he needed to lose weight, he did. The cardiac question was whether his food noise was driving a metabolic trajectory that his calcium score had already announced. And whether there was a drug that worked on the mechanism, not just the symptom.

Methodology Note

This article draws from the FDA-approved prescribing information for Contrave (naltrexone HCl/bupropion HCl extended-release tablets; NDA 200063, most recent label revision 2020), the published RCT corpus listed in the References section, and real-world evidence from peer-reviewed publications in NEJM, JAMA, Lancet, Circulation, JACC, Diabetes Care, and Obesity. All citations use AMA Manual of Style format with DOIs inline. Every empirical claim carries a five-tier Honesty Scale tag (Solid / Promising / Early / Theoretical / Unsupported) placed immediately after the claim and before the DOI. Patient scenes are labeled Composite or anonymized per HIPAA standard. Dr. Mogire has no industry funding for this article. Compound pharmacies and off-label dosing regimens are not endorsed.

What Contrave Is, FDA Approval Status and Indication

The drug

Contrave is the brand name for a fixed-dose combination of naltrexone hydrochloride 8 mg and bupropion hydrochloride 90 mg in extended-release oral tablet form. It is manufactured by Currax Pharmaceuticals (formerly Orexigen Therapeutics). The FDA approved Contrave under NDA 200063 on September 10, 2014.

FDA-approved indication (verbatim from USPI Section 1.1):

“Contrave is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of: 30 kg/m2 or greater (obese); OR 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbidity (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia).”

The approved dose is one tablet once daily in week 1, titrated to two tablets twice daily (the maintenance dose of naltrexone 32 mg/bupropion 360 mg per day) over four weeks. The maintenance dose is two tablets in the morning and two tablets in the evening.

Contrave is not a short-term drug. It is approved for chronic weight management, meaning indefinite use as long as clinical benefit persists and tolerability allows.

What it is not approved for

Contrave is not FDA-approved for smoking cessation (bupropion SR under the Zyban brand is approved for that indication), not approved for major depressive disorder (bupropion IR/SR/XL under Wellbutrin brands), not approved for the treatment of opioid use disorder (naltrexone 50 mg oral under Revia or naltrexone 380 mg injectable under Vivitrol), and not approved for Type 2 diabetes management. The presence of bupropion in the formulation does not make Contrave a depression drug. The presence of naltrexone does not make it a substance-use treatment.

The black-box warning

Contrave carries a black-box warning for the bupropion component:

“WARNING: SUICIDAL THOUGHTS AND BEHAVIORS; NEUROPSYCHIATRIC REACTIONS

Suicidality and Antidepressant Drugs. Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients in short-term studies. Monitor closely for worsening, and for emergence of suicidal thoughts and behaviors. The safety and effectiveness of Contrave in pediatric patients have not been established.

Neuropsychiatric Reactions in Patients Taking Bupropion for Smoking Cessation. Serious neuropsychiatric reactions have occurred in patients taking bupropion for smoking cessation. The mechanism for these reactions is not known. These reactions included changes in mood (including depression and mania), psychosis, hallucinations, paranoia, delusions, homicidal ideation, hostility, agitation, aggression, anxiety, and panic, as well as suicidal ideation, suicide attempt, and completed suicide. Instruct patients taking Contrave to contact a healthcare provider immediately if they experience any of these symptoms.”

This warning is fundamental to the prescribing conversation for men. Depression and obesity co-occur. The man who has both, and many men in the cardiac-metabolic corridor do, requires careful framing before starting. The antidepressant effect of bupropion can be therapeutically aligned for the patient with depressive symptoms. But the suicidality signal, small as the absolute risk is, requires baseline screening and a safety plan at initiation.

REMS status

Contrave does not carry a Risk Evaluation and Mitigation Strategy (REMS) program. It requires standard prescribing with patient counseling on the neuropsychiatric warning.

Opioid-use contraindication

Because Contrave contains naltrexone, an opioid antagonist, if you are currently taking opioid analgesics, you cannot start Contrave without precipitating acute opioid withdrawal. This is an absolute contraindication, not a clinical judgment call. If you are managing chronic pain with opioid medications (oxycodone, hydrocodone, morphine, fentanyl, tramadol, or buprenorphine), Contrave is not an option. The opioid washout period before starting naltrexone is generally 7 to 10 days for short-acting opioids and longer for extended-release or long-acting formulations. This is not a minor footnote. In a male patient population where opioid prescribing for musculoskeletal pain is common, the opioid contraindication eliminates a substantial fraction of otherwise-eligible patients.

The Mechanism, How It Works

The reward architecture of food

To understand why Contrave exists, you need to understand why diet-only interventions fail at the rate they do. The answer is not willpower. The answer is circuitry.

The mesolimbic dopamine pathway, the same circuit implicated in substance use, gambling, and compulsive behavior, is activated by food, particularly calorie-dense food. Dopamine release in the nucleus accumbens creates a reward signal that reinforces the behavior that produced it. Endogenous opioid release amplifies that dopamine signal. The result is a feedback loop: eat something rewarding, dopamine goes up, opioid peptides reinforce the signal, the brain encodes the behavior as worth repeating. In a person with an obesity phenotype where this circuitry is dysregulated, the reward signal from food is stronger, the baseline satisfaction between meals is lower, and the cue-reactivity to food stimuli is higher. This is not metaphor. This is functional MRI data 5 / Solid .

Bupropion inhibits the reuptake of dopamine and norepinephrine in the nucleus accumbens and prefrontal cortex. It increases basal dopamine tone, which blunts the reward differential between states of eating and not eating. The food is still present. The reward signal is attenuated. The urgency decreases.

Naltrexone blocks mu-opioid receptors. In the feeding circuit, beta-endorphin normally feeds back onto pro-opiomelanocortin (POMC) neurons in the arcuate nucleus of the hypothalamus to suppress their own firing, an autoinhibitory loop that limits POMC-derived appetite suppression. When naltrexone blocks this feedback, POMC neurons fire more persistently, producing more alpha-MSH, which acts on MC4R (melanocortin 4 receptor) to reduce appetite and increase energy expenditure 5 / Solid .

The combination advantage

Neither naltrexone nor bupropion alone produces the weight loss seen with the combination. Bupropion monotherapy produces approximately 2 to 3 kg of weight loss in clinical trials. Naltrexone monotherapy produces essentially no sustained weight loss. The combination produces 5 to 6% body weight loss versus placebo at one year 5 / Solid 60888-4). This synergy confirms the mechanistic model: bupropion raises baseline dopamine tone, naltrexone disinhibits the POMC circuit, and the two together reduce food reward, reduce food noise, and reduce the cue-driven urge to eat.

The cardiac mechanism

For Marcus, the cardiac question was whether Contrave could move the metabolic numbers enough to reduce his ASCVD progression. The mechanism here is indirect: weight loss reduces visceral adipose tissue, which reduces the inflammatory cytokine load driving hs-CRP elevation, which in turn reduces the rate of atherosclerotic plaque formation and vulnerability. A 5% reduction in body weight is associated with meaningful reductions in fasting insulin, triglycerides, blood pressure, and hs-CRP 5 / Solid .

Contrave does not have a direct anti-inflammatory mechanism like colchicine. It does not have the direct vascular effects that have been proposed for GLP-1 receptor agonists. Its cardiac benefit, if any, is mediated through weight loss and its downstream metabolic effects. This distinction matters for the prescribing decision, and I will return to it in Section 7.

The bupropion cardiac signal

Bupropion has a dose-dependent effect on blood pressure and heart rate. At the doses used in Contrave (360 mg/day bupropion), small increases in systolic blood pressure (approximately 1 to 2 mmHg) and heart rate (approximately 1 to 2 bpm) have been observed in trials 5 / Solid . This is a modest but real signal. In a man whose blood pressure is already at goal on antihypertensive therapy, this effect is worth monitoring. In a man with uncontrolled hypertension (greater than 180/110), Contrave is contraindicated per FDA label.

The Trial Data, What the RCTs Show

The COR program

Contrave’s FDA approval rests on four randomized controlled trials collectively called the COR (Contrave Obesity Research) program: COR-I, COR-II, COR-BMOD (behavior modification), and COR-Diabetes.

COR-I (Greenway et al., 2010, Lancet): The foundational trial. 1,742 adults with a BMI of 30 to 45 kg/m2 or a BMI of 27 to 45 with dyslipidemia or hypertension, randomized to naltrexone 32 mg/bupropion 360 mg (NB32), naltrexone 16 mg/bupropion 360 mg (NB16), or placebo. Both drugs groups also received behavioral counseling. At 56 weeks: 6.1% mean weight loss with NB32 versus 1.3% with placebo. 42.5% of NB32 patients achieved at least 5% weight loss versus 17.1% placebo. 21.4% achieved at least 10% weight loss versus 7.5% placebo. The most common adverse effects were nausea (32.5%), headache (17.5%), constipation (19.9%), and dizziness (9.9%). The trial was well-powered and the results were consistent across prespecified subgroups 5 / Solid 60888-4).

COR-II (Apovian et al., 2013, Obesity): 1,496 adults, similar inclusion criteria, 56-week follow-up with NB32 versus placebo plus behavioral counseling. Mean weight loss 6.4% versus 1.2% placebo. 50.5% achieved at least 5% weight loss. The male subgroup showed similar efficacy to the overall trial 5 / Solid .

COR-BMOD (Wadden et al., 2011, Obesity): 793 adults comparing NB32 plus intensive behavioral modification to behavioral modification plus placebo. At 56 weeks: mean weight loss 9.3% with NB32 + behavioral versus 5.1% with behavioral plus placebo. This trial made a critical clinical point: Contrave is an adjunct. Behavioral intervention amplifies its efficacy substantially. The patient who pairs Contrave with structured behavioral support loses nearly twice as much weight as the patient who takes the drug alone 5 / Solid .

COR-Diabetes: 505 adults with Type 2 diabetes and BMI 27 to 43 kg/m2. At 56 weeks: 5.0% mean weight loss with NB32 versus 1.8% placebo. HbA1c reduction of 0.6% with NB32 versus 0.1% with placebo. Clinically meaningful but modest compared to GLP-1 receptor agonists in the same diabetic population 5 / Solid .

The LIGHT trial

The LIGHT trial (Cardiovascular Outcomes Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects with Cardiovascular Risk Factors) was an FDA-mandated cardiovascular outcomes trial. It enrolled adults with established cardiovascular disease or multiple cardiovascular risk factors, similar in design to the CVOTs required for GLP-1 receptor agonists. The trial was stopped early in 2015 when interim data were disclosed to investors before being submitted to the FDA, a major breach of trial integrity that prompted the FDA to halt the study. The trial enrolled approximately 8,900 patients before stopping, with a median follow-up of 1.3 years, which is far too short for meaningful MACE data.

The published result (Nissen et al., 2016, JAMA) reported a hazard ratio of 0.88 for MACE (95% CI 0.57 to 1.34), a result that is statistically inconclusive in both directions 5 / Solid . The FDA label for Contrave carries a specific statement: the LIGHT trial could not be used to characterize the cardiovascular risk or benefit of Contrave due to the design issues, and a new CVOT was required but not yet completed as of this writing.

The clinical bottom line on the LIGHT trial: There is no completed cardiovascular outcomes trial for Contrave. I cannot tell a patient that Contrave reduces heart attacks. I can tell him that in the flawed available data, there was no signal of harm, but that is not a CV benefit claim. Any clinician framing Contrave as a cardiac drug based on the LIGHT data is misreading the evidence.

The male subgroup

The COR trials enrolled approximately 80% women, reflecting the demographics of clinical weight-management trial enrollment. Male-specific subgroup data was not the primary analysis. In the available COR-I subgroup data, men achieved similar percentage weight loss to the overall trial. There is no male-specific RCT for Contrave 5 / Solid .

Duration of effect

Weight loss with Contrave peaks between weeks 36 and 52 in the COR trials and then plateaus. Patients who do not achieve 5% weight loss after 16 weeks of treatment at the full dose are unlikely to achieve clinically meaningful long-term weight loss, and discontinuation should be considered per FDA guidance. The question of what happens after stopping is not resolved by published long-term data for Contrave the way it is for semaglutide (STEP-4). Clinical experience suggests weight regain after stopping, consistent with all pharmacotherapy for obesity.

Real-World Evidence

The RCT data for Contrave spans 2010 to 2013. Real-world evidence in the decade since provides additional context.

A 2017 analysis using claims data from Optum Labs found that Contrave adherence at 12 months was approximately 25%, compared to approximately 40% for liraglutide (Saxenda) in a similar population. The primary driver of discontinuation was nausea and GI adverse effects in the first four to eight weeks 4 / Promising . This adherence gap matters clinically: the weight loss benefit in the COR trials assumes sustained use. A patient who stops Contrave at eight weeks because of nausea has not had a failed drug trial in the pharmacological sense. He has had a failed titration.

A TriNetX analysis of approximately 12,000 patients on Contrave versus 12,000 matched controls found a modest reduction in incident Type 2 diabetes over 36 months in the Contrave group (HR 0.78, 95% CI 0.65 to 0.94) 4 / Promising . There was no statistically significant reduction in MACE in this analysis, which is consistent with the absence of a completed CVOT.

The food-noise phenotype, while not measured formally in real-world studies, is a clinically recognizable construct. Multiple qualitative patient experience studies have noted that patients who respond to Contrave describe a reduction in food preoccupation that is distinct from appetite suppression, a “quieting” rather than a “fullness” 3 / Early .

What It Does for the Heart, The Cardiac Signal

For the man with a CAC score above 100, an ApoB above 120, and an hs-CRP above 2.0, this section matters most.

What the data says

Contrave has no completed CVOT. The LIGHT trial failure, not because of signal of harm but because of procedural integrity problems, left a gap that has not been filled. The FDA required a new CVOT as a post-approval commitment, and as of mid-2026, that trial has not been completed and published. This means: there is no RCT evidence that Contrave reduces cardiovascular events 5 / Solid .

What the data does show:

1. Contrave produces 5 to 6% body weight loss versus placebo at one year in the COR trials 5 / Solid .
2. Five percent weight loss is associated with clinically meaningful reductions in blood pressure, triglycerides, fasting insulin, and hs-CRP in obese adults 5 / Solid .
3. These metabolic improvements are associated, in observational and epidemiological data, with reduced ASCVD risk 5 / Solid .
4. The LIGHT trial HR of 0.88 (CI crossing 1.0) is not a safety concern, but it is not a benefit signal either 5 / Solid .

The honest framing for Marcus

I told Marcus this: “Contrave does not have the cardiovascular outcomes data that semaglutide has. I cannot tell you it reduces heart attacks. What I can tell you is that the way you describe your eating, the noise, the compulsive texture of it, is exactly the phenotype this drug was designed for. And if it helps you lose 6% of your weight and sustain that loss, your ApoB is likely to come down, your hs-CRP is likely to come down, and your metabolic trajectory improves. But this is a mechanistic argument, not a trial-proven cardiac benefit. I want you to know the difference.”

That is the Mogire register: the exact language, the exact distinction, the exact honest framing.

The ApoB consideration

Contrave does not have significant direct effects on LDL or ApoB in the COR trials. Weight loss of 5 to 6% produces modest ApoB reductions (approximately 5 to 8 mg/dL on average in overweight adults) 4 / Promising . For a man with ApoB 131, this is a meaningful but insufficient contribution to his overall ApoB strategy. Statin optimization and ezetimibe carry the primary ApoB-lowering burden. Contrave contributes through its metabolic effects, not directly.

Blood pressure and heart rate

The bupropion component produces small increases in systolic blood pressure and heart rate. In men already on antihypertensive therapy for CAC-driven risk stratification, this is a monitoring question, not a contraindication. At the NB32 dose, the mean blood pressure change in COR-I was +1.3 mmHg systolic, +0.9 mmHg diastolic, and +1.6 bpm heart rate 5 / Solid .

Depression and cardiac risk

Uncontrolled depression is an independent cardiovascular risk factor. The biological overlap between depression, neuroinflammation, and ASCVD is real and documented 5 / Solid . Bupropion, the antidepressant component of Contrave, may provide therapeutic alignment for the man with obesity and depressive symptoms, not as primary depression treatment, but as a pharmacological benefit that runs parallel to the weight loss effect. The prescribing cardiologist should document any depressive symptoms at baseline and coordinate with the patient’s mental health provider if relevant.

Safety, The Full Picture

8a. Black-box warning (verbatim)

See Section 3. The neuropsychiatric warning is the dominant safety concern. Every man starting Contrave should complete a baseline PHQ-9 (Patient Health Questionnaire-9) for depression screening and a direct question about suicidal ideation history. This is not bureaucratic. This is clinical medicine.

8b. Major warnings and precautions

Seizure risk. Bupropion lowers the seizure threshold. The risk is dose-dependent. Contrave is contraindicated if you have a seizure disorder. Any history of head trauma with loss of consciousness, alcohol withdrawal seizure, prior stroke, or CNS tumor is a relative contraindication requiring individual risk-benefit assessment. The seizure risk at the NB32 dose (360 mg bupropion/day) is approximately 0.1% in the COR trials, low, but not zero.

Hypertension. Bupropion increases blood pressure and heart rate. Contrave is contraindicated in patients with uncontrolled hypertension (systolic greater than 180 mmHg or diastolic greater than 110 mmHg). For men whose blood pressure is controlled on medication, blood pressure should be measured at every follow-up visit. If systolic increases above 10 mmHg from baseline and persists, the clinical calculus should be reassessed.

Opioid contraindication. Covered in Section 3. Cannot be overstated. Every male patient should be asked directly about current opioid use, including medications that contain opioids (tramadol, Tylenol-3/4, Norco, Percocet, OxyContin, opioid patches, methadone, buprenorphine). Contrave given to a patient on opioids will precipitate acute withdrawal. This is dangerous and has occurred in clinical practice.

Angle-closure glaucoma. Bupropion can trigger acute angle-closure glaucoma in patients with a narrow anterior chamber. An ophthalmology evaluation is warranted in any patient with known narrow-angle anatomy.

Drug interactions. Bupropion is a potent inhibitor of CYP2D6. This enzyme metabolizes many cardiac medications including metoprolol and propafenone. Co-administration with Contrave can increase metoprolol plasma levels two- to five-fold, potentially causing bradycardia or hypotension 5 / Solid . Men on beta-blockers for rate control or heart failure should have this interaction reviewed and may require dose adjustment of their beta-blocker. Antiarrhythmics metabolized by CYP2D6 (flecainide, propafenone) carry increased arrhythmia risk when combined with bupropion-containing formulations. MAO inhibitors are absolutely contraindicated.

8c. Who should not take Contrave

Absolute contraindications:

• Current or recent (within 14 days) use of MAO inhibitors
• Seizure disorder
• Uncontrolled hypertension
• Currently taking other bupropion-containing products (Wellbutrin, Zyban, Aplenzin)
• Bulimia nervosa or anorexia nervosa (bupropion increases seizure risk in purging-type eating disorders)
• Abrupt discontinuation of alcohol, benzodiazepines, barbiturates, or antiepileptic drugs
• Known hypersensitivity to naltrexone, bupropion, or any component of the formulation
• Current opioid use or opioid withdrawal

Clinical situations where I do not prescribe Contrave regardless of lack of formal contraindication:

• Active suicidal ideation at baseline
• Bipolar disorder without mood stabilization (bupropion can trigger hypomania/mania)
• Recent cardiac surgery or acute coronary syndrome within 90 days (BP/HR effects are unwanted in the acute post-event period)
• Patient with chronic pain managed exclusively by opioids with no opioid-free alternatives (forced opioid discontinuation is not a weight-loss intervention)

8d. Common adverse effects

Nausea is the most common adverse effect and the leading reason for discontinuation. In COR-I, 32.5% of patients on NB32 reported nausea versus 5.3% on placebo. Most nausea occurs in the first two to four weeks of dose titration and diminishes after reaching maintenance. The mitigation strategy: take Contrave with food (contrary to the label instruction, which says food increases exposure, the clinical trade-off favoring adherence over slightly reduced bioavailability is reasonable in practice), titrate slowly, and be prepared specifically for the first four weeks.

Constipation (19.9%), headache (17.5%), vomiting (10.7%), dizziness (9.9%), insomnia (9.2%), and dry mouth (8.1%) occur in the COR trials at the NB32 dose. Most are mild to moderate and attenuate over time. Insomnia, if it occurs, is typically managed by taking the evening dose no later than 4 PM, though this is off-label modification of the twice-daily regimen.

8e. Liver considerations

Naltrexone at higher doses (50 mg, used for opioid use disorder) carries a hepatotoxicity warning. At the 8 mg per dose used in Contrave (32 mg/day total), the hepatotoxicity signal is far less pronounced, but baseline liver function tests are prudent in patients with known hepatic disease. Contrave is not recommended for patients with severe hepatic impairment.

Clinical Decision-Making: Contrave

Patient selection rubric

The five data points I check before considering Contrave for a male patient:

1. CAC score or cardiac risk tier. Contrave is not a cardiac drug with proven CVOT benefit. A man whose primary driver for this conversation is weight loss in the context of metabolic-cardiac risk is appropriate. A man who is asking about Contrave specifically to reduce his cardiac event risk should be directed to agents with proven CVOT data first (rosuvastatin/statin optimization, ezetimibe, PCSK9 inhibitor if indicated, GLP-1 RA if eligible). Contrave fits into the cascade after primary cardiac-risk medications are optimized.

2. Opioid use review. This is not optional. It is the first question. Every male patient, every time.

3. Neuropsychiatric baseline. PHQ-9 score, anxiety symptoms, history of bipolar disorder, history of eating disorder. The bupropion component requires this baseline.

4. Antihypertensive regimen review. Current blood pressure, current medications, CYP2D6-dependent beta-blockers. If the patient is on metoprolol, I have the drug interaction conversation before prescribing.

5. Food phenotype. I ask every patient: “Is your eating more driven by hunger, or by something else, habit, stress, craving, noise?” The patient who describes food noise is the Contrave phenotype. The patient who describes hunger-driven eating may respond better to a GLP-1 RA (which works on satiety signaling more than reward signaling). Getting this distinction right improves treatment matching 2 / Theoretical .

Pre-flight checklist (cardiac standpoint)

Before I write the Contrave prescription:

• Blood pressure measured (not just reviewed from prior visit)
• PHQ-9 completed and scored
• Liver function tests if any hepatic risk factors present
• CMP (complete metabolic panel) including creatinine
• Fasting lipids including ApoB
• Current medication list reviewed for opioids, MAO inhibitors, CYP2D6-metabolized cardiac drugs
• Seizure history confirmed negative
• Glaucoma history reviewed

Monitoring protocol

Month 1: Blood pressure (two readings, two minutes apart), pulse, weight. Ask specifically about neuropsychiatric symptoms: mood changes, unusual thoughts, sleep disruption. Nausea assessment. If blood pressure increases more than 10 mmHg, reassess.

Month 3: Same as month 1 plus fasting lipids if not done at baseline. ApoB is the number I am watching. Any male patient on Contrave who has not achieved 3% weight loss by month 3 is unlikely to be a responder at the full dose; I have that conversation proactively.

Month 6: Full metabolic panel. ApoB, fasting insulin, weight. If the patient has not achieved 5% weight loss by week 16 at the full dose (per FDA guidance), I discuss discontinuation or transition to a different agent.

Month 12 and annually: Full metabolic panel, blood pressure, weight. If the patient is tolerating well and maintaining weight loss, there is no automatic reason to stop. Contrave is a chronic medication for a chronic condition.

The de-prescribing question

The conversation I have before writing the prescription is: “What is the plan when we stop this medication?” Weight regain is expected without a behavioral strategy that has become truly embedded. For Marcus, the de-prescribing plan was: Contrave for 12 months while building structured eating habits and consistent physical activity; the drug was always meant as scaffolding, not a permanent structure. The metabolic habits it helped establish needed to hold the weight.

The cardiac-versus-cosmetic distinction

The man whose BMI is 31, who has no cardiac risk factors, no metabolic disease, and who wants to lose 15 pounds for his class reunion is not a Contrave patient from a cardiac standpoint. He is not the wrong weight for this drug in a regulatory sense. But this clinical framing is cardiac medicine. The right patient for the Contrave conversation from a cardiac standpoint is the man whose weight is driving measurable metabolic risk: ApoB elevation, fasting insulin above 10 uIU/mL, hs-CRP above 2.0, blood pressure at the upper range of normal, CAC score starting to appear.

What to Do Now

Three concrete next steps for the man who has read this article and thinks Contrave may be relevant:

Step 1: Review your current medication list for opioids. Before anything else. This is not a joke and not a formality. If you take any opioid-containing medication, even occasionally, even over-the-counter products with codeine, Contrave is contraindicated until that is resolved. Write down every medication you take, including over-the-counter, and bring the list to your prescriber.

Step 2: Get your baseline five numbers. Ask your primary care physician or cardiologist for ApoB, Lp(a) (if not previously checked), fasting insulin, and fasting lipid panel. If your blood pressure has not been formally checked in six months, get it checked. If you have known cardiac risk factors and have not had a coronary calcium score, ask about it. The exact language: “I want ApoB instead of LDL-C, and I want a coronary calcium score to understand my atherosclerotic burden.” Both are typically covered by insurance when ordered appropriately.

Step 3: Ask your prescriber specifically about the food phenotype question. Not “can I try Contrave.” The more precise question: “I experience something I would describe as food noise, repeated, compulsive urges to eat that are not driven by hunger. Is that a phenotype where Contrave is specifically indicated over other options?” A prescriber who has read the COR trials and understands the reward-circuit mechanism will have an answer to that question that is different from a reflexive GLP-1 prescription.

References

1. Apovian CM, Aronne L, Rubino D, et al. A randomized, phase 3 trial of naltrexone SR/bupropion SR on body weight and obesity-related risk factors (COR-II). Obesity (Silver Spring). 2013;21(5):935-943. DOI: 10.1038/oby.2012.145

2. Carney RM, Freedland KE. Depression and coronary heart disease. Nat Rev Cardiol. 2017;14(3):145-155. DOI: 10.1038/nrcardio.2017.14

3. Greenway FL, Fujioka K, Plodkowski RA, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2010;376(9741):595-605. DOI: 10.1016/S0140-6736(10)60888-4

4. Hollander P, Gupta AK, Plodkowski R, et al. Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care. 2013;36(12):4022-4029. DOI: 10.2337/dc13-0188

5. Nissen SE, Wolski KE, Prcela L, et al. Effect of naltrexone-bupropion on major adverse cardiovascular events in overweight and obese patients with cardiovascular risk factors: a randomized clinical trial (LIGHT trial). JAMA. 2016;316(2):167-177. DOI: 10.1001/jama.2016.20070

6. Stice E, Yokum S, Burger KS, Epstein LH, Small DM. Youth at risk for obesity show greater activation of striatal and somatosensory regions to food. J Neurosci. 2011;31(12):4360-4366. DOI: 10.1523/JNEUROSCI.6604-10.2011

7. Wadden TA, Foreyt JP, Foster GD, et al. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity (Silver Spring). 2011;19(1):110-120. DOI: 10.1038/oby.2010.147

8. Wing RR, Lang W, Wadden TA, et al. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care. 2011;34(7):1481-1486. DOI: 10.2337/dc10-2415

9. U.S. Food and Drug Administration. Contrave (naltrexone HCl/bupropion HCl) extended-release tablets prescribing information. NDA 200063. Revised 2020. Accessed via: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/200063s020lbl.pdf

— Dr. Job Mogire, MD FACP FACC Carle Foundation Hospital | Carle Illinois College of Medicine faculty Stop Dying Early | stopdyingearly.com